%PDF-1.4
%
75 0 obj
<>
endobj
72 0 obj
<>
endobj
129 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-02T16:41:32Z
2024-03-29T01:50:16-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T01:50:16-07:00
application/pdf
Heather
201312.dec
uuid:bfc285ca-1dd1-11b2-0a00-3908277d8900
uuid:bfc285cc-1dd1-11b2-0a00-d30000000000
endstream
endobj
61 0 obj
<>
endobj
62 0 obj
<>
endobj
76 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
30 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
38 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
41 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
155 0 obj
[159 0 R]
endobj
156 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 57 714.5293 Tm
[(10.)-875 (Loizou S, Cofiner C, )17.8 (W)79.8 (eetman )54.9 (AP)110.8 (, )17.8 (W)79.8 (alport MJ. Immunoglobulin)]TJ
2.175 -1.25 Td
(class and IgG subclass distribution of anticardiolipin antibodies in)Tj
0 -1.25 TD
(patients with systemic lupus erythematosus and associated)Tj
T*
(disorders. Clin Exp Immunol 1992;90:434-9.)Tj
-2.1381 -1.25 Td
[(1)36.9 (1.)-875 (Roubey RA, Maldonado MA, Byrd SN. Comparison of an enzyme-)]TJ
2.1381 -1.25 Td
(linked immunosorbent assay for antibodies to beta 2-glycoprotein I)Tj
T*
[(and a conventional anticardiolipin immunoassay)64.9 (. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1996;39:1606-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (McNally )17.7 (T)73.9 (, Mackie IJ, Machin SJ, Isenber)17.7 (g DA. Increased levels of)]TJ
0 Tc 2.175 -1.25 Td
(beta 2 glycoprotein-I antigen and beta 2 glycoprotein-I binding)Tj
T*
(antibodies are associated with a history of thromboembolic)Tj
T*
(complications in patients with SLE and primary antiphospholipid)Tj
T*
(syndrome. Br J Rheumatol 1995;34:1031-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875.1 (Amengual O, )54.8 (Atsumi )17.7 (T)73.9 (, Khamashta MA, Koike )17.7 (T)73.9 (, Hughes GR)79.7 (V)129.1 (.)]TJ
0 Tc 2.175 -1.25 Td
[(Specificity of ELISA)-220.1 (for antibody to beta 2-glycoprotein I in)]TJ
T*
(patients with antiphospholipid syndrome. Br J Rheumatol)Tj
0 Tw T*
(1996;35:1239-43.)Tj
0.0249 Tw -2.175 -1.25 Td
[(14.)-875 (T)69.8 (an EM, Cohen )54.8 (AS, Fries JF)79.8 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Harris EN, Pierangeli S, Birch D. )54.8 (Anticardiolipin wet workshop)]TJ
0 Tc 2.175 -1.25 Td
(report. Fifth International Symposium on antiphospholipid)Tj
T*
[(antibodies. )54.9 (Am J Clin Pathol 1994;101:616-24.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (Bertolaccini ML, )54.8 (Atsumi )17.7 (T)73.9 (, Khamashta MA, )54.8 (Amengual O, Hughes)]TJ
0 Tc 2.175 -1.25 Td
[(GR)79.8 (V)129.1 (. )54.9 (Autoantibodies to human prothrombin and clinical)]TJ
T*
(manifestations in 207 patients with systemic lupus erythematosus. )Tj
T*
[(J Rheumatol 1998;25:1)36.9 (104-8.)]TJ
-2.175 -1.25 Td
[(17.)-875 (Atsumi )17.7 (T)74 (, Ieko M, Bertolaccini ML, et al. )54.8 (Association of)]TJ
2.175 -1.25 Td
(autoantibodies against the phosphatidylserine-prothrombin complex)Tj
T*
(with manifestations of the antiphospholipid syndrome and with the)Tj
T*
[(presence of lupus anticoagulant. )54.9 (Arthritis Rheum 2000;43:1982-93.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(18.)-875.1 (Brandt JT)73.9 (, )17.7 (T)34.8 (riplett DA, )54.8 (Alving B, Scharrer I. On behalf of the)]TJ
0 Tc 2.175 -1.25 Td
[(Subcommitee on Lupus )54.9 (Anticoagulant/Antiphospholipid )54.9 (Antibody)]TJ
T*
(of the Scientific and Standardisation Committee of the ISTH.)Tj
T*
(Criteria for the diagnosis of lupus anticoagulants: an update.)Tj
T*
[(Thromb Haemost 1995;74:1)36.9 (185-90.)]TJ
-2.175 -1.25 Td
[(19.)-875 (Kalunian KC, Peter JB, Middlekauf)17.8 (f HR, et al. Clinical significance)]TJ
2.175 -1.25 Td
(of a single test for anti-cardiolipin antibodies in patients with)Tj
T*
[(systemic lupus erythematosus. )54.8 (Am J Med 1988;85:602-8.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875.1 (W)79.7 (eidmann CE, )17.7 (W)79.7 (allace DJ, Peter JB, Knight PJ, Bear MB,)]TJ
2.175 -1.25 Td
[(Klinenber)17.7 (g JR. Studies of IgG, IgM and IgA)-220.2 (antiphospholipid)]TJ
0 Tc T*
(antibody isotypes in systemic lupus erythematosus. J Rheumatol)Tj
0 Tw T*
(1988;15:74-9.)Tj
-0.00011 Tc 0.02499 Tw 30.825 52.5 Td
[(21.)-875.1 (Merkel P)91.7 (A, Chang )36.8 (Y)129.1 (, Pierangeli SS, Convery K, Harris EN,)]TJ
0 Tc 2.175 -1.25 Td
[(Polisson RP)110.8 (. )17.7 (The prevalence and clinical associations of)]TJ
T*
[(anticardiolipin antibodies in a lar)17.8 (ge inception cohort of patients)]TJ
T*
[(with connective tissue diseases. )54.9 (Am J Med 1996;101:576-83.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(22.)-875.1 (Escalante )54.8 (A, Brey RL, Mitchell BD Jr)39.7 (, Dreiner U. )54.8 (Accuracy of)]TJ
0 Tc 2.175 -1.25 Td
(anticardiolipin antibodies in identifying a history of thrombosis)Tj
T*
[(among patients with systemic lupus erythematosus. )54.8 (Am J Med)]TJ
0 Tw T*
(1995;98:559-65.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (Molina JF)79.7 (, Gutierrez-Urena S, Molina J, et al. )17.7 (V)111 (ariability of)]TJ
0 Tc 2.175 -1.25 Td
(anticardiolipin antibody isotype distribution in 3 geographic)Tj
T*
(populations of patients with systemic lupus erythematosus. )Tj
T*
(J Rheumatol 1997;24:291-6.)Tj
-2.175 -1.25 Td
[(24.)-875 (Diri E, Cucurull E, Gharavi )54.8 (AE, et al. )54.8 (Antiphospholipid \(Hughes\222\))]TJ
2.175 -1.25 Td
[(syndrome in )54.8 (African-Americans: IgA)-220.1 (aCL)-238.2 (and abeta2 glycoprotein-)]TJ
T*
(I is the most frequent isotype. Lupus 1999;8:263-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(25.)-875.1 (W)39.7 (ilson )17.7 (W)110.7 (A, Faghiri Z, )17.7 (T)69.7 (aheri F)79.7 (, Gharavi )54.8 (AE. Significance of IgA)]TJ
0 Tc 2.175 -1.25 Td
[(antiphospholipid antibodies. Lupus 1998;7:S1)36.9 (10-3.)]TJ
-2.175 -1.25 Td
[(26.)-875 (Lockshin MD, Sammaritano LR, Schwartzman S. )17.7 (V)111.1 (alidation of the)]TJ
2.175 -1.25 Td
[(Sapporo criteria for antiphospholipid syndrome. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(2000;43:440-3.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875.1 (Fanopoulos D, )17.7 (T)69.7 (eodorescu MR, )17.7 (V)111 (a)0.1 (r)17.7 (ga J, )17.7 (T)69.7 (eodorescu M. High)]TJ
2.175 -1.25 Td
[(frequency of abnormal levels of IgA)-220.2 (anti-beta2-glycoprotein I)]TJ
0 Tc T*
(antibodies in patients with systemic lupus erythematosus:)Tj
T*
(relationship with antiphospholipid syndrome. J Rheumatol)Tj
0 Tw T*
(1998;25:675-80.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(28.)-875.1 (T)69.7 (sutsumi )54.8 (A, Matsuura E, Ichikawa K, Fujisaku )54.8 (A, Mukai M, Koike)]TJ
0 Tc 2.175 -1.25 Td
[(T)74 (.)0.1 ( IgA)-220.1 (class anti-beta2-glycoprotein I in patients with systemic)]TJ
T*
(lupus erythematosus. J Rheumatol 1998;25:74-8.)Tj
-2.175 -1.25 Td
[(29.)-875 (Cucurull E, Gharavi )54.8 (AE, Diri E, Mendez E, Kapoor D, Espinoza)]TJ
2.175 -1.25 Td
[(LR. IgA)-220.1 (anticardiolipin and anti-beta2-glycoprotein I are the most)]TJ
T*
[(prevalent isotypes in )54.8 (African )54.8 (American patients with systemic lupus)]TJ
T*
[(erythematosus. )54.9 (Am J Med Sci 1999;318:55-60.)]TJ
-2.175 -1.25 Td
[(30.)-875 (Abinader )54.8 (A, Hanly )54.8 (AJ, Lozada CJ. Catastrophic antiphospholipid)]TJ
-0.00011 Tc 2.175 -1.25 Td
(syndrome associated with anti-beta-2-glycoprotein I IgA.)Tj
0 Tc T*
(Rheumatology 1999;38:84-5.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(31.)-875.1 (Y)100 (amada H, )17.7 (T)69.7 (sutsumi )54.8 (A, Ichikawa K, Kato EH, Koike )17.7 (T)73.9 (,)-0.1 ( Fujimoto)]TJ
0 Tc 2.175 -1.25 Td
(S. IgA-class anti-beta2-glycoprotein I in women with unexplained)Tj
T*
[(recurrent spontaneous abortion. )54.9 (Arthritis Rheum 1999;42:2727-8.)]TJ
-2.175 -1.25 Td
[(32.)-875 (Lee RM, Branch DW)91.8 (, Oshiro BT)74 (, Rittenhouse L, Orcutt )54.8 (A, Silver)]TJ
2.175 -1.25 Td
[(RM. IgA)-220.1 (beta2 glycoprotein-I antibodies are elevated in women)]TJ
T*
(with unexplained recurrent spontaneous abortion and unexplained)Tj
-0.00011 Tc T*
[(fetal death [abstract]. J )54.8 (Autoimmun 2000;15:A63.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
0 Tc 8 0 0 8 54.5 35.9844 Tm
[(Bertolaccini, et al: IgA)-257.2 (aPL)-257.2 (in lupus)]TJ
0 Tw 60.9375 -0.0313 Td
(2643)Tj
ET
0 0 0 0 scn
/GS0 gs
100.89 58.54 407.5 -10.83 re
f*
0.5 w
100.89 58.54 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
114 0 obj
<>
endobj
134 0 obj
<>
endobj
80 0 obj
<>
endobj
78 0 obj
<>
endobj
79 0 obj
<>
endobj
108 0 obj
<>stream
HV pUL!BzI$c8}8@r$8 3`L8*)PQ*,["
jR"A(9@"b!$\Z}~3 :
'ۿ7(K@N ݀XYR3_?ma,uڠꙕ/? b|eas| _Q(z(uҧ_ч4%tM|GFRU@$]XP+!h,۸exWW͛oݤţm}ܲ|(uL $iT" NoMBZܡz_J
?jDžz}XE\F@FJc
qQxv<VT(:Q^c$mKX8SI(`@/csU0ҳJ610<8*m_['r"w!DWK8'z2ϚKȁ1>J'8-Jk{Etbb>wXЄ;b[&uRэ>C1qa&V3n#39.⒈p/AqRzL٩:nm2O3]pU
n]\IgduUQW+a$p}|rn!HDk;n-}8ΜCЄCD"џ'oY#!GsJ2LR5ohuGgZs/Yegn%L'R^n/f채c9>|_r83*Cn6>QD'GHHnVm/&Xԉ%M v/aV2O4H.qyR~+/kg%JIU\!5OnbZVmwfPMrX1VUc-6ZJF#a#XIbٛ:s3اy3\bf?.#$ T99CfFyh(>Q$\T9uQWpo3Mb!+⦸j2ZvbgdGRe\/?[䟥)w#2Wb4?WWeY٢lUSZ{}徚T'>4Z'-[hlU-5h;3݈~pLrXXhF
T6K/*+DK||u*Ika1(ǻNjcJJPuĻ{ҕgY:07)F?f(9e>lrSvtAp¿$z'5Ń],Y{{=v%,nU~bo݁LzX5a1g^`*쯲B"lFjiNCh$&Hs{i7ၡ432sm"aaA_wVlT;u3B>(ͺ\vV4zPLƬku'';Д~[&=6^{w;w/8o}p:0@Lu쀝_jjKM
M(Rj
I(jC7sGRGofoy;c-LOįZ6gUG<^
b)H| u()lūI%ķ3oq2Wav| =p7(wlrP76 >``v5 . 1֝=^;w|@}TGxdrGO#OKrv[ˏ}4u1?9rC,w9
9l;gglBAV ? Ne>rcd>i@{Rw5/`ʱd{lv1:#tGƜca2
D*hNMԪA NdY'o: I?@N(:y M'5tC Y' $0@> A'{: `@:٥e b KYr
ځpk+*J]
)*ם\[..eKڥ|ԥ\]#EڢL(-`RӢ,nQZgvqCÐIH)!"~%_g33<">
r,)